Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach

Sophie Taylor; Enrico Pierluigi Spugnini; Yehuda G. Assaraf; Tommaso Azzarito; Cyril Rauch; Stefano Fais

doi:10.1016/j.drup.2015.08.004

journal article Nov 01, 2015

Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach

Sophie Taylor Enrico Pierluigi Spugnini Yehuda G. Assaraf Tommaso Azzarito Cyril Rauch Stefano Fais

Drug Resistance Updates Vol. 23 pp. 69-78 · Elsevier BV

View at Publisher Save 10.1016/j.drup.2015.08.004

Topics

No keywords indexed for this article. Browse by subject →

References

143

[1]

Ackerman "Hypoxia, lipids, and cancer: surviving the harsh tumor microenvironment" Trends Cell Biol. (2014) 10.1016/j.tcb.2014.06.001

[2]

Adar "Imidazoacridinone-dependent lysosomal photodestruction: a pharmacological Trojan horse approach to eradicate multidrug-resistant cancers" Cell Death Dis. (2012) 10.1038/cddis.2012.30

[3]

Altan "Defective acidification in human breast tumor cells and implications for chemotherapy" J. Exp. Med. (1998) 10.1084/jem.187.10.1583

[4]

Assaraf "Molecular basis of antifolate resistance" Cancer Metastasis Rev. (2007) 10.1007/s10555-007-9049-z

[5]

Azzarito "Lansoprazole induces sensitivity to suboptimal doses of paclitaxel in human melanoma" Cancer Lett. (2015) 10.1016/j.canlet.2014.10.017

[6]

Bach "IGF-binding proteins—the pieces are falling into place" Trends Endocrinol. Metabol. (2005) 10.1016/j.tem.2005.05.005

[7]

Barathova "Alternative splicing variant of the hypoxia marker carbonic anhydrase IX expressed independently of hypoxia and tumour phenotype" Br. J. Cancer (2008) 10.1038/sj.bjc.6604111

[8]

Barar "Dysregulated pH in tumor microenvironment checkmates cancer therapy" Bioimpacts (2013)

[9]

Bailey "Targeting the metabolic microenvironment of tumors" Adv. Pharmacol. (2012) 10.1016/b978-0-12-397927-8.00004-x

[10]

Bellone "The acidity of the tumor microenvironment is a mechanism of immune escape that can be overcome by proton pump inhibitors" Oncoimmunology (2013) 10.4161/onci.22058

[11]

Biernacka "Hyperglycaemia-induced chemoresistance of prostate cancer cells due to IGFBP2" Endocr. Relat. Cancer (2013) 10.1530/erc-13-0077

[12]

Brambilla "P-glycoprotein binds to ezrin at amino acid residues 149–242 in the FERM domain and plays a key role in the multidrug resistance of human osteosarcoma" Int. J. Cancer (2012) 10.1002/ijc.26285

[13]

Calcinotto "Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes" Cancer Res. (2012) 10.1158/0008-5472.can-11-1272

[14]

Cekanova "Animal models and therapeutic molecular targets of cancer: utility and limitations" Drug Des. Dev. Ther. (2014) 10.2147/dddt.s49584

[15]

Chen "The Warburg effect and its cancer therapeutic implications" J. Bioenerg. Biomembr. (2007) 10.1007/s10863-007-9086-x

[16]

Chen "Involvement of tumor macrophage HIFs in chemotherapy effectiveness: mathematical modeling of oxygen, pH, and glutathione" PLoS ONE (2014) 10.1371/journal.pone.0107511

[17]

Chit "The opportunity cost of capital: development of new pharmaceuticals" Inquiry (2015)

[18]

Christofk "The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth" Nature (2008) 10.1038/nature06734

[19]

Coventry "Australian multi-center experience outside of the Sydney Melanoma Unit of isolated limb infusion chemotherapy for melanoma" J. Surg. Oncol. (2014) 10.1002/jso.23590

[20]

Damaghi "pH sensing and regulation in cancer" Front. Physiol (2013) 10.3389/fphys.2013.00370

[21]

Dang "The interplay between MYC and HIF in cancer" Nat. Rev. Cancer (2008) 10.1038/nrc2274

[22]

Daniel "The role of proton dynamics in the development and maintenance of multidrug resistance in cancer" Biochim. Biophys. Acta (2013) 10.1016/j.bbadis.2013.01.020

[23]

De Milito "Tumor acidity, chemoresistance and proton pump inhibitors" Future Oncol. (2005) 10.2217/14796694.1.6.779

[24]

De Milito "Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species" Cancer Res. (2007) 10.1158/0008-5472.can-06-4095

[25]

De Milito "pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity" Int. J. Cancer (2010) 10.1002/ijc.25009

[26]

De Milito "A rationale for the use of proton pump inhibitors as antineoplastic agents" Curr. Pharm. Des. (2012) 10.2174/138161212799504911

[27]

DiMasi "Clinical approval success rates for investigational cancer drugs" Clin. Pharmacol. Ther. (2013) 10.1038/clpt.2013.117

[28]

DiMasi "Pharmaceutical R&D performance by firm size: approval success rates and economic returns" Am. J. Ther. (2014) 10.1097/mjt.0b013e318269198f

[29]

Drori "Potentiation of anticancer-drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane permeability" Eur. J. Biochem. (1995) 10.1111/j.1432-1033.1995.tb20352.x

[30]

Durzyńska "IGF axis and other factors in HPV-related and HPV-unrelated carcinogenesis (review)" Oncol. Rep. (2014) 10.3892/or.2014.3505

[31]

Ellegaard "Sunitinib and SU11652 inhibit acid sphingomyelinase, destabilize lysosomes, and inhibit multidrug resistance" Mol. Cancer Ther. (2013) 10.1158/1535-7163.mct-13-0084

[32]

Elzein "Regulation of human growth hormone receptor expression by microRNAs" Mol. Endocrinol. (2014) 10.1210/me.2014-1183

[33]

Fais "Targeting vacuolar H+-ATPases as a new strategy against cancer" Cancer Res. (2007) 10.1158/0008-5472.can-07-1805

[34]

Fais "Proton pump inhibitor-induced tumour cell death by inhibition of a detoxification mechanism" J. Intern. Med. (2010) 10.1111/j.1365-2796.2010.02225.x

[35]

Fais "TM9 and cannibalism: how to learn more about cancer by studying amoebae and invertebrates" Trends Mol. Med. (2012) 10.1016/j.molmed.2011.09.001

[36]

Fais "Microenvironmental acidosis in carcinogenesis and metastases: new strategies in prevention and therapy" Cancer Metastasis Rev. (2014) 10.1007/s10555-014-9531-3

[37]

Federici "Exosome release and low pH belong to a framework of resistance of human melanoma cells to cisplatin" PLoS ONE (2014) 10.1371/journal.pone.0088193

[38]

Ferrari "Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patients’ bed" J. Transl. Med (2013) 10.1186/1479-5876-11-268

[39]

Frantz "Cofilin is a pH sensor for actin free barbed end formation: role of phosphoinositide binding" J. Cell Biol. (2008) 10.1083/jcb.200804161

[40]

Fukamachi "Expression of acidosis-dependent genes in human cancer nests" Mol. Clin. Oncol. (2014) 10.3892/mco.2014.344

[41]

Gatenby "Acid-mediated tumor invasion: a multidisciplinary study" Cancer Res. (2006) 10.1158/0008-5472.can-05-4193

[42]

Gerweck "Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics" Mol. Cancer Ther. (2006) 10.1158/1535-7163.mct-06-0024

[43]

Gillies "pH imaging. A review of pH measurement methods and applications in cancers" IEEE Eng. Med. Biol. Mag. (2004) 10.1109/memb.2004.1360409

[44]

Gonen "Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance" Drug Resist. Updates (2012) 10.1016/j.drup.2012.07.002

[45]

Gotink "Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance" Clin. Cancer Res. (2011) 10.1158/1078-0432.ccr-11-1667

[46]

Gottesman "Mechanisms of cancer drug resistance" Annu. Rev. Med. (2002) 10.1146/annurev.med.53.082901.103929

[47]

Hashim "Imaging pH and metastasis" NMR Biomed. (2011) 10.1002/nbm.1644

[48]

Ho Kim "The action of HIF-3α variants on HIF-2α-HIF-1β heterodimer formation is directly probed in live cells" Exp. Cell Res. (2015) 10.1016/j.yexcr.2015.06.017

[49]

Hogendoorn "Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up" Ann. Oncol. (2010) 10.1093/annonc/mdq223

[50]

Huang "HIF-1-mediated suppression of acyl-CoA dehydrogenases and fatty acid oxidation is critical for cancer progression" Cell Rep. (2014) 10.1016/j.celrep.2014.08.028

Showing 50 of 143 references

Cited By

229

Logic‐Gated DNA Intelligent Nanorobots for Cellular Lysosome Interference and Enhanced Therapeutics

Ruixue Chang, Xiuping Li · 2025

Angewandte Chemie International Edi...

Nanotechnology-based approaches overcome lung cancer drug resistance through diagnosis and treatment

Junnan Li, Lipeng Zhu · 2023

Drug Resistance Updates

The role of NF-κB in breast cancer initiation, growth, metastasis, and resistance to chemotherapy

Eluri Pavitra, Jyothsna Kancharla · 2023

Biomedicine & Pharmacotherapy

Dysregulated Signalling Pathways Driving Anticancer Drug Resistance

Nauf Bou Antoun, Athina-Myrto Chioni · 2023

International Journal of Molecular...

Why may citrate sodium significantly increase the effectiveness of transarterial chemoembolization in hepatocellular carcinoma?

Philippe Icard, Luca Simula · 2021

Drug Resistance Updates

Anticancer drug resistance: An update and perspective

Ruth Nussinov, Chung-Jung Tsai · 2021

Drug Resistance Updates

Extracellular acidity and increased exosome release as key phenotypes of malignant tumors

Mariantonia Logozzi, Enrico Spugnini · 2019

Cancer and Metastasis Reviews

How the Warburg effect supports aggressiveness and drug resistance of cancer cells?

Philippe Icard, Seth Shulman · 2018

Drug Resistance Updates

Long non-coding RNAs: An emerging powerhouse in the battle between life and death of tumor cells

Xing-dong Xiong, Xingcong Ren · 2016

Drug Resistance Updates

Metrics

229

Citations

143

References

Details

Published: Nov 01, 2015
Vol/Issue: 23
Pages: 69-78
License: View

Authors

S

Sophie Taylor

E

Enrico Pierluigi Spugnini

5Department of Drug Research and Evaluation, Section of Pharmacogenetic, Drug Resistance and Experimental Therapeutics, Istituto Superiore di Sanità, Rome, Italy

Cite This Article

Sophie Taylor, Enrico Pierluigi Spugnini, Yehuda G. Assaraf, et al. (2015). Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach. Drug Resistance Updates, 23, 69-78. https://doi.org/10.1016/j.drup.2015.08.004

Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach

You May Also Like